1222TiP TroFuse-022/ENGOT-ov84/GOG-3103 part 1: A phase III study of sacituzumab tirumotecan (Sac-TMT) ± bevacizumab (Bev) maintenance therapy vs standard of care (SoC) after second-line (2L) platinum-based doublet chemotherapy (chemo) for platinum-sensitive recurrent ovarian cancer (PSROC) | Publicación